These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 24440279)

  • 1. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
    Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
    Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
    Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
    Paz-Ares L; Hirsh V; Zhang L; de Marinis F; Yang JC; Wakelee HA; Seto T; Wu YL; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong TJ; Peña C; Smit EF; Mok TS
    J Thorac Oncol; 2015 Dec; 10(12):1745-53. PubMed ID: 26743856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH
    Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
    Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
    J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Wang WL; Tang ZH; Xie TT; Xiao BK; Zhang XY; Guo DH; Wang DX; Pei F; Si HY; Zhu M
    Asian Pac J Cancer Prev; 2014; 15(14):5691-6. PubMed ID: 25081687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.
    Ma JY; Yan HJ; Gu W
    J Cancer Res Ther; 2015; 11(2):397-402. PubMed ID: 26148607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
    Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.